2025-07-08 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare solutions.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -2.95%
*   **VOO Cumulative Return:** 95.42%
*   **Deviation:**
    *   Maximum: 23.1
    *   Minimum: -99.5
    *   Current: -97.2
    *   Relative Deviation: 1.9

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO). The current deviation is close to the historical minimum, indicating a substantial underperformance relative to the benchmark. The relative deviation of 1.9 suggests MRK's performance is near the bottom of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta    | Cap(B) |
|------------|---------|--------|----------|---------|--------|
| 2015-2017  | 5.0%    | 58.2%  | -24.0%   | -0.0    | 134.8  |
| 2016-2018  | 43.0%   | 66.4%  | 25.0%    | -0.1    | 183.0  |
| 2017-2019  | 40.0%   | 66.4%  | 11.0%    | 0.3     | 217.9  |
| 2018-2020  | 20.0%   | 66.4%  | 0.0%     | 0.3     | 195.9  |
| 2019-2021  | -1.0%   | 65.6%  | -50.0%   | 0.3     | 192.4  |
| 2020-2022  | 13.0%   | 69.5%  | 11.0%    | 0.3     | 278.5  |
| 2021-2023  | 31.0%   | 69.5%  | 13.0%    | 0.3     | 273.7  |
| 2022-2024  | -7.0%   | 69.5%  | -33.0%   | 0.2     | 249.7  |
| 2023-2025  | -55.0%  | 61.4%  | -102.0%  | 0.4     | 203.2  |

**Analysis:**

*   **CAGR:** Fluctuating CAGR values indicate variable growth rates over different periods, with recent years showing negative growth.
*   **MDD:** High Maximum Drawdown (MDD) values across all periods suggest significant risk or volatility in the stock's price.
*   **Alpha:** Consistently negative Alpha values in recent periods (2019-2025) suggest underperformance compared to the benchmark, while earlier periods (2016-2019) had positive Alpha values, indicating outperformance.
*   **Beta:** Beta values consistently range from 0.2 to 0.4, indicating a moderate positive correlation with the market. The low Beta suggests that MRK is less sensitive to market movements than the S&P 500.
*   **Cap(B):** Market capitalization fluctuates over the years, indicating variations in investor valuation and confidence. The declining capitalization in recent periods (2023-2025) might reflect investor concerns about the company's performance.

### 2. Recent Price Movement

*   **Current Price:** 80.93
*   **Last Market Data:** {'price': 80.915, 'previousClose': 80.93, 'change': -0.02}
*   **5-day Moving Average:** 80.5777
*   **20-day Moving Average:** 80.0289
*   **60-day Moving Average:** 79.169

**Analysis:** The current price is slightly above all three moving averages (5, 20, and 60-day), suggesting a short-term upward trend. However, the minimal change in the last market data indicates relatively stable recent price action.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 46.15
*   **PPO:** 0.2382
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-day Relative Deviation Change:** 1.7 (+) (Short-term Increase)
*   **Expected Return (%):** -545.9%

**Analysis:**

*   The low MRI suggests relatively low market risk.
*   The RSI of 46.15 is neutral, indicating neither overbought nor oversold conditions.
*   The PPO is slightly positive, indicating a possible bullish trend but is quite modest.
*   The Hybrid Signal suggests a cautious buy, allocating 80% of cash.
*   The recent increase in relative deviation indicates a short-term upward trend.
*   The extremely negative expected return suggests significant potential underperformance compared to the S&P 500 over the long term.

### 4. Recent News & Significant Events

*   **2025-07-07:** Major business developments, regulatory changes, or market events.
*   **2025-07-06:** Analyst discussions on recent performance and outlook.
*   **2025-07-04:** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-05:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news indicates both volatility and analyst scrutiny of Merck's performance. It's crucial to investigate these events further to understand their specific impact.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-05-02 | 2.01  | 15.53 B$   |
| 2024-11-06 | 1.25  | 16.66 B$   |
| 2024-08-05 | 2.15  | 16.11 B$   |
| 2024-05-03 | 1.88  | 15.78 B$   |
| 2025-05-02 | 1.88  | 15.78 B$   |

**Analysis:** The most recent EPS and revenue figures show some fluctuation. Need to compare against expectations and historical trends to assess performance.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-03-31 | $48.34B    | 10.51%    |
| 2024-12-31 | $46.31B    | 8.08%     |
| 2024-09-30 | $44.50B    | 7.09%     |
| 2024-06-30 | $43.58B    | 12.52%    |
| 2024-03-31 | $40.36B    | 11.80%    |

**Analysis:**

*   **Revenue and Profitability:**
    *   Revenue: Revenue has fluctuated over the quarters, with the highest revenue reported in Q3 2024 ($16.66B).
    *   Profit Margin: Profit margins remain consistently high, ranging between 75.50% and 77.98%, indicating strong operational efficiency and pricing power.
*   **Capital and Profitability:**
    *   Equity: Total equity has generally increased over the quarters, indicating growth in the company's net asset value.
    *   ROE: Return on Equity (ROE) has fluctuated, with the highest ROE in Q2 2024 (12.52%). The overall trend shows variability in the efficiency of equity utilization.

### 7. Overall Summary

Based on the data provided:

*   **Underperformance:** MRK has significantly underperformed the S&P 500, with a large negative deviation.
*   **Volatility:** The stock exhibits considerable volatility, as indicated by the high MDD values.
*   **Recent Trends:** Short-term technical indicators suggest a slight upward trend, but long-term expected returns are extremely negative.
*   **Financial Health:** The company maintains strong profit margins, but revenue and earnings fluctuate. Equity is generally growing, but ROE is variable.
*   **News and Events:** Recent news suggests potential catalysts and challenges.

**Conclusion:** MRK appears to be facing significant challenges, reflected in its underperformance and negative expected returns. However, the company's strong financial base and recent positive price action might present opportunities. Investors should closely monitor recent news and analyze the underlying causes of the company's underperformance before making any investment decisions. Further investigation into the reasons for negative alpha and the major business developments mentioned in the news is crucial.

